Announcements Trials

Browse Landscape

Phase

Phase 2 17 Phase 3 8 Phase 1/2 7 Phase NA 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

HER2-positive Breast Cancer 1

Interventions

Cisplatin 17 Magnetic Resonance Spectroscopy 16 Specimen Handling 13 pembrolizumab 10 Carboplatin 10 Gemcitabine 9 Paclitaxel 8 Radiotherapy 7 Radiation 7 Platinum 7 1,2-diaminocyclohexaneplatinum II citrate 7 Pemetrexed 6 Nivolumab 6 Doxorubicin 6 Surgical Procedures, Operative 5 Radiotherapy, Intensity-Modulated 5 Docetaxel 5 Dexamethasone 5 Biopsy 5 atezolizumab 4 Rituximab 4 Immunoglobulin G 4 Disulfides 4 Bevacizumab 4 Temozolomide 3 Standard of Care 3 Ramucirumab 3 Drug Therapy 3 Cyclophosphamide 3 Cetuximab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Trastuzumab × 30 days × Clear all

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡